DelveInsight’s “Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Spontaneous Urticaria market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Chronic Spontaneous Urticaria drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Spontaneous Urticaria treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Spontaneous Urticaria: An Overview
Urticaria is a common and heterogeneous inflammatory skin disorder with or without associated angioedema. It presents with wheals, angioedema, or both due to activation and degranulation of skin mast cells, followed by the release of histamine and other mediators leading to sensory nerve activation, vasodilatation, plasma extravasation, and cellular recruitment. It is classified as acute or chronic; acute urticaria is present for less than 6 weeks, while chronic urticaria lasts more than 6 weeks.
Chronic urticaria is further classified as chronic induced urticaria (CIndU) and chronic spontaneous urticaria (CSU). CIndU has definite and subtype-specific triggers that induce signs and symptoms, while Chronic Spontaneous Urticaria is endogenous and independent of external causes.
Chronic Spontaneous Urticaria can persist for months or even years, but can also resolve spontaneously in many cases. The appearance of hives is unpredictable and can occur without a specific trigger. Chronic Spontaneous Urticaria is believed to involve immune system dysfunction, with activation of mast cells and release of histamine. Autoimmunity and other underlying factors may play a role in some cases.
Chronic Spontaneous Urticaria Market Key Facts
-
The Chronic Spontaneous Urticaria Market size in the 7MM was approximately USD 2,084.6 million in 2022 and is projected to increase during the forecast period (2023-2032).
-
The market size of chronic spontaneous urticaria in the US will increase at a CAGR of 9.5% during the study period due to increasing awareness of the disease and the launch of the emerging therapy. The market size was approximately USD 1,104.4 million in 2022.
-
The total market size of chronic spontaneous urticaria in EU4 and the UK was calculated to be approximately USD 600.8 million in 2022, which was nearly 28.8% of the total market revenue for the 7MM.
-
In 2022, the total diagnosed prevalent cases of chronic urticaria were estimated to be approximately 4,154,234 cases in the 7MM. These cases are expected to decrease by 2032.
-
Among the 7MM, the United States accounted for nearly 18.7% of the total diagnosed prevalent cases of chronic urticaria in 2022. These cases are expected to increase during the study period (2019-2032).
-
In 2022, among the EU4 and the UK countries, Germany accounted for the highest diagnosed prevalent cases of chronic spontaneous urticaria, followed by France. While Spain accounted for the least diagnosed, prevalent cases of chronic spontaneous urticaria. While Japan accounted for nearly 37.9% of the total diagnosed prevalent cases of chronic spontaneous urticaria in the 7MM.
-
Women are twice as likely as men to be diagnosed with the disease, and most people first develop symptoms between 20 and 40.
Chronic Spontaneous Urticaria Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Spontaneous Urticaria pipeline therapies. It also thoroughly assesses the Chronic Spontaneous Urticaria market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Chronic Spontaneous Urticaria drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chronic Spontaneous Urticaria Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Chronic Spontaneous Urticaria epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Spontaneous Urticaria epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Chronic Spontaneous Urticaria Epidemiology, Segmented as –
-
Total Prevalent cases of Chronic Spontaneous Urticaria in the 7MM [2019-2032]
-
Gender-Specific cases of Chronic Spontaneous Urticaria in the 7MM [2019-2032]
-
Age-specific cases of Chronic Spontaneous Urticaria in the 7MM [2019-2032]
-
Total diagnosed and Treatable prevalent cases of Chronic Spontaneous Urticaria in the 7MM [2019-2032]
Chronic Spontaneous Urticaria Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Spontaneous Urticaria market or expected to be launched during the study period. The analysis covers the Chronic Spontaneous Urticaria market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Spontaneous Urticaria drugs based on their sale and market share.
The report also covers the Chronic Spontaneous Urticaria pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Spontaneous Urticaria companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chronic Spontaneous Urticaria Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market
Chronic Spontaneous Urticaria Therapeutics Analysis
The initial treatment for Chronic Spontaneous Urticaria involves the use of H1-antihistamines. Further, other medications, including corticosteroids, leukotriene receptor antagonists, and XOLAIR (omalizumab), are prescribed for more severe or refractory cases. XOLAIR is the only approved monoclonal antibody indicated for treating CSU. It selectively binds to human immunoglobulin E (IgE) and lowers free IgE levels.
There are several unmet needs in Chronic Spontaneous Urticaria management, including developing more effective long-term treatment options, personalized approaches, improved understanding of underlying mechanisms, patient education, support, and increased accessibility to affordable treatments. Several drugs are being investigated to cater to the unmet needs of CSU patients. The late-stage candidates under development include remibrutinib, DUPIXENT, FASENRA, lirentelimab, and TEZSPIRE.
Several major pharma and biotech companies are developing therapies for Chronic Spontaneous Urticaria. Currently, Sanofi is leading the therapeutics market with its Chronic Spontaneous Urticaria drug candidates in the most advanced stage of clinical development.
Chronic Spontaneous Urticaria Companies Actively Working in the Therapeutics Market Include
-
United BioPharma
-
Teva Pharmaceuticals Development, Inc.
-
Amgen
-
Novartis Pharmaceuticals
-
Allakos Inc.
-
Sanofi
-
Celltrion
-
Celldex Therapeutics
-
MICROBIO GROUP.
-
Escient Pharmaceuticals
-
Jasper Therapeutics
-
Glenmark Pharmaceuticals
-
Taiho Pharmaceuticals
-
ValenzaBio
-
Carna Biosciences
-
Servier
And Many Others
Emerging and Marketed Chronic Spontaneous Urticaria Therapies Covered in the Report Include:
-
Dupilumab: Sanofi
-
Tezepelumab: Amgen
-
Barzolvolimab: Celldex Therapeutics
-
DUPIXENT (dupilumab): Sanofi/Regeneron
-
Remibrutinib (LOU064): Novartis Pharmaceuticals
-
Lirentelimab (AK002): Allakos/BioWa
-
XOLAIR (omalizumab): Roche/Novartis
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Spontaneous Urticaria Competitive Intelligence Analysis
4. Chronic Spontaneous Urticaria Market Overview at a Glance
5. Chronic Spontaneous Urticaria Disease Background and Overview
6. Chronic Spontaneous Urticaria Patient Journey
7. Chronic Spontaneous Urticaria Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Chronic Spontaneous Urticaria Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Spontaneous Urticaria Unmet Needs
10. Key Endpoints of Chronic Spontaneous Urticaria Treatment
11. Chronic Spontaneous Urticaria Marketed Therapies
12. Chronic Spontaneous Urticaria Emerging Drugs and Latest Therapeutic Advances
13. Chronic Spontaneous Urticaria Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Spontaneous Urticaria Market Outlook (In US, EU5, and Japan)
16. Chronic Spontaneous Urticaria Companies Active in the Market
17. Chronic Spontaneous Urticaria Access and Reimbursement Overview
18. KOL Views on the Chronic Spontaneous Urticaria Market
19. Chronic Spontaneous Urticaria Market Drivers
20. Chronic Spontaneous Urticaria Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Undifferentiated Pleomorphic Sarcoma Market
“Undifferentiated Pleomorphic Sarcoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Undifferentiated Pleomorphic Sarcoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Undifferentiated Pleomorphic Sarcoma market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research